CAR T-Cell Therapy: A New Era in Cancer Treatments

A big thank you to Reese Ladak for submitting their MIMM 214 assignment to post on The Turret. This guest post may give you new hope about the future of cancer treatments!

______________________________________________________________

CAR T-Cell Therapy: A New Era in Cancer Treatments

Reese Ladak

“I’m sorry, the test came back positive. You have cancer.” – are words that no patient ever wishes to hear. Characterized by rapid and uncontrollable proliferation of cells, cancer research has the most funding–and with good reason, given how cancer death rates have decreased only 32% in males and 17% in females in 30 years (Close, 2015). Although conventional treatments like chemotherapy and radiation are effective, more than 35% of cancer patients in the US alone died in 2018 (Siegel, et al., 2018). Oncology treatments thus far have been not as effective as they are mentally, physically, and financially taxing on a person. This, however, will not be the case for much longer. Due to extensive research by scientists and biomedical engineers, a new branch of cancer treatment, CAR T-cell therapy, is on the rise (Maus, et al., 2014). In the near future, patients sitting in a doctor’s office will no longer skip a heartbeat when they hear the word “cancer.”

What is it?

As the name suggests, CAR T-cell therapy involves T cells, which are soldiers of the body that protect it from harm. Each T cell has a specific pathogen (or “enemy”) of the body that it targets and subsequently destroys. In CAR T-cell therapy, the pathogens are solely cancer cells, courtesy of the chimeric antigen receptor (CAR) (Pagel, 2017). The science behind CAR is simple: only cancerous cells carry the specific molecule which CAR has strong affinity for, and hence all the T cells carrying CAR will be targeted towards just cancerous cells (Guthrie, 2019). With that said, CAR inducing a higher degree of selectivity in T cells is the reason behind CAR T-cell therapy’s increased effectiveness compared to chemotherapy. The more conventional treatments, such as chemotherapy, are untargeted forms of treatment, meaning both cancerous and healthy cells are victims. Hence, the undesirable side effects of conventional cancer treatments, including hair loss, are no longer a concern for patients. Not only is it safer than chemotherapy, CAR T-cell therapy is much more convenient. With chemotherapy, patients must receive daily treatments. Contrastingly, patients undergoing CAR T-cell therapy require only one treatment, since CAR T cells autonomously fight the cancer to eradication (Tripathy, 2017).

Is it effective?

Based on a study done in 2016, where multiple CAR T-cell therapies were administered, it is! This study was trying to find the best way for CAR T-cell therapy to target cancerous cells, by evaluating different target molecules on cancerous cells that CAR may have high affinity towards. The study indicated that CAR T-cell therapy shows great potential. Based on the data based on more than 8,000 patients, it was apparent that blood cancers are much more treatable than solid tumours through CAR T-cell therapy. Furthermore, it was found that CD19 was the target molecule that was the most effective; a remarkable 80% of patients were completely cured of their cancer. The study also addressed a few flaws of CAR T-cell therapy, but, fortunately, they are quite manageable, and their severity is insignificant compared to that of cancer (Almåsbak, Aarvak, & Vemuri, 2016).

Should I care?

Yes, you definitely should – even if cancer is not a relevant part of your life. Cancer has been tormenting us for too long with requiring expensive, time-consuming and less than ideal treatments. Although current CAR T-cell treatments are far from perfect, such as being expensive and not 100% targeted towards cancerous cells, it is a major improvement from existing treatments–and it is only going to get better in the future. Current studies are trying to improve the selectivity of CAR T-cell therapy on blood cancers, as well as to introduce a way for the therapy to target solid tumours effectively (Sendra, 2018). Hence, a future where patients no longer have to worry about cancer is imminent.

References

  • Almåsbak, H., Aarvak, T., & Vemuri, M. C. (2016). CAR T Cell Therapy: A Game Changer in Cancer Treatment. Journal of Immunology Research,2016, 1-10. doi:10.1155/2016/5474602
  • Close, K. (2015, August 03). JAMA Paper Breaks Down Medical Research Funding in the US. Retrieved from https://diatribe.org/jama-paper-breaks-down-medical-research-funding-us
  • Guthrie, G. (2019, January 24). CAR T-Cell Immunotherapy: The 2018 Advance of the Year. Retrieved from https://www.cancer.net/blog/2018-01/car-t-cell-immunotherapy-2018-advance-year
  • Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood,123(17), 2625-2635. doi:10.1182/blood-2013-11-492231
  • Pagel, J. M. (2017, November 01). Chimeric Antigen Receptor (CAR) T-Cell Therapy. Retrieved from https://jamanetwork.com/journals/jamaoncology/fullarticle/2652907
  • Sendra, J. W. (2018, May 23). What You Need to Know About CAR T-Cell Therapy for Cancer. Retrieved from https://healthblog.uofmhealth.org/cancer-care/what-you-need-to-know-about-car-t-cell-therapy-for-cancer
  • Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians,68(1), 7-30. doi:10.3322/caac.21442
  • Tripathy, D. (2017, March 19). Weighing the Benefits and Risks of CAR T-Cell Therapy: The Stakes Are High. Retrieved from https://www.curetoday.com/publications/cure/2017/hematology-1-2017/weighing-the-benefits-and-risks-of-car-tcell-therapy-the-stakes-are-high

 

An active Science Literacy Week

This year, Science Literacy Week will keep you moving. Beginning September 16, there are tours lined up, a game-based session around data management, a hands-on Excel workshop, interactive sound demonstrations, and exhibits to explore.

Here is the daily rundown of downtown activities organized by the Library:

Monday, (Sept 16): Montreal’s Urban Heat Island: Tour of temperature sensors on campus

Tuesday, (Sept 17): Tour of the Maude Abbott Medical Museum

Wednesday, (Sept 18): Sounds in the City + Treasures from the History of Science in Rare Books and Special Collections

Thursday, (Sept 19): Tour of the Steinberg Centre for Simulation and Interactive Learning + Discover the cure! An introduction to the fundamentals of data management

Friday, (Sept 20): Chart Making in Excel: Going Further by Telling a Story with your Data

Register for an event today!

We also have exhibits going on so don’t miss out on those. You will get the opportunity to test out your map literacy in the Redpath Library Building, and check out a science book in person or online.

Student recommendation for the NHL

Congratulations goes out to Mark Kumhyr, winner of the Winter/Summer 2018 Communication in Engineering (CCOM 206) Excellence in Written Communication Award!

Alternate Refrigeration Systems for Improving Ice Quality in NHL Arenas

The National Hockey League is a multibillion-dollar industry, and yet suffers from a recent uptick in complaints over sub-par ice quality, largely due to a warming climate and higher average ice rink temperatures. The objective of this paper is to demonstrate the superiority of an indirect ammonia/CO2 refrigeration system over a direct CO2 system, all in relation to the current indirect ammonia/brinewater system. The comparison will be made based on three criteria: efficiency, represented by the coefficient of performance value; cost, taking into account short- and long-term investments; and environmental effect, presented as a Global Warming Potential value. The results show that the indirect ammonia/CO2 system is 56% more efficient than the current system, and 20% more than the direct CO2 system, and is less costly in the long-term. The environmental effects of each refrigerant systems were shown to be negligible. It is recommended that the NHL implement an indirect ammonia/CO2 system in order to negate the warming arena temperatures, and ensure that the NHL remains a powerhouse in the sports industry.

Read the full paper in eScholarship, McGill’s open access repository.